Research Library

Cancer drug shortages are almost uniquely associated with generic drugs (small profit margins) and rarely with patented drugs (large profit margins). They are common in the U.S., but uncommon in Europe and elsewhere, where generic drug prices are on average higher than in the U.S. This suggests the main cause of drug shortages is economic.

Exorbitant prices for cancer drugs harm patients who cannot afford to take their medicines.

Baker Institute health policy experts Hagop M. Kantarjian and Vivian Ho explain why Texas, which holds the notorious record of the highest rate of uninsured citizens in the U.S., should follow many Republican-led states that are now reconsidering the Medicaid expansion program under Obamacare.

Many contemporary medical ethicists dismiss the centuries-old Hippocratic Oath as outdated because of the enormous scientific, social, economic, and political changes since Hippocrates' time. Health policy scholar Hagop Kantarjian makes a case for its relevance.

Every patient with cancer or another life-threatening disease wants the most effective treatment, but drug prices have become staggering. What determines the escalating prices of cancer drugs?

For both generic and patented cancer drugs, the free-market economy has not worked well. Solutions are needed to maintain reasonable drug prices that allow for corporate profits and are affordable to patients and to the U.S. health care system.

In a genuine effort to protect patients from adverse events, regulatory burdens and research rigidity in clinical trials have increased to a point at which such protection is outweighing the benefits, and actually harming patients who are unable to be involved in clinical trials.

Allowing the producer-dominated market to set drug prices has spiraled the cost of cancer drugs out of control. Drug pricing can be reduced while preserving the profit-making incentive, by linking price to a true measure of quality: preservation and meaningful prolongation of life.

Altering the Medicare policy on injectable drugs is one way to reduce Medicare expenditures. Allowing self-administration will also free up hospital and clinic capacity for other patients.